Humacyte Inc expected to post a loss of 10 cents a share - Earnings Preview

Humacyte

07/08/2026 17:22

Humacyte Inc HUMA.OQ HUMA.O is expected to  show a rise in quarterly revenue when it reports  results on August 12 for the period ending June 30 2026
The Durham North Carolina-based  company is expected to report a 270.8% increase in revenue to $1.116 million from $301 thousand a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Humacyte Inc is for a loss of 10 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Humacyte Inc is $2.00, about 181.8% above its last closing price of $0.71
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.12
-0.12
-0.09
Beat
22.5
Dec. 31 2026
-0.13
-0.13
Met
1.3
Sep. 30 2025
-0.16
-0.16
-0.11
Beat
30.5​
Jun. 30 2025
-0.16
-0.16
-0.24
Missed
-48.5
​​Mar. 31 2025
-0.18
-0.19
0.28
Beat
247.4
Dec. 31 2024
-0.27
-0.25
-0.16
Beat
36​
Sep. 30 2024
-0.25
-0.25
-0.33
Missed
-32.8
Jun. 30 2024
-0.24
-0.24
-0.48
Missed
-101.7
This summary was machine generated August 7 at 16:22 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)